#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13274	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2140	617.0	0	.	n	.	0	A69G	SNP	69	69	A	303	303	G	689	G	647	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13274	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2140	617.0	0	.	n	.	0	C1450T	SNP	1450	1450	C	1684	1684	T	745	T	685	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13274	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2140	617.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1418	1418	C	806	C,T	752,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24434	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3479	699.8	0	.	n	.	0	T695C	SNP	695	695	T	966	966	C	750	C,T	696,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24434	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3479	699.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2242	2242	C	795	C,T	719,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24434	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3479	699.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2316	2316	A	794	A	747	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24434	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3479	699.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	2868	2868	C	776	C	726	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
blaTEM.WHO_M_pConjugative_00003	blaTEM.WHO_M_pConjugative_00003	1	0	16	6	blaTEM	861	272	100.0	blaTEM.l6.c30.ctg.1	272	1.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Betalactam resistance
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	1760	folP	855	855	100.0	folP.l15.c4.ctg.1	1420	123.2	1	SNP	p	R229S	1	.	.	685	687	AGC	984	986	AGC	201;201;201	A;G;C	186;187;186	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4846	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3415	141.4	1	SNP	p	S91F	1	.	.	271	273	TTC	531	533	TTC	153;153;155	T;T;C	138;137;140	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4846	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3415	141.4	1	SNP	p	D95G	1	.	.	283	285	GGC	543	545	GGC	148;145;145	G;G;C	130;128;130	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4846	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3415	141.4	1	SNP	p	G95N	0	.	.	283	285	GGC	543	545	GGC	148;145;145	G;G;C	130;128;130	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1614	mtrR	633	633	99.84	mtrR.l15.c30.ctg.1	1290	124.7	0	.	p	.	0	D79N	NONSYN	235	237	GAT	538	540	AAT	215;210;208	A;A,T;T	194;187,1;185	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1614	mtrR	633	633	99.84	mtrR.l15.c30.ctg.1	1290	124.7	1	SNP	p	G45D	0	.	.	133	135	GGC	436	438	GGC	189;190;191	G;G;C	170;171;171	mtrR.WHO_U_01459:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	772	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c17.ctg.1	1035	74.0	0	.	n	.	0	A197.	DEL	197	197	A	660	660	A	178	A	170	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4510	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2964	151.6	0	.	p	.	0	E91G	NONSYN	271	273	GAG	586	588	GGG	170;169;169	G;G;G	158;159;159	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4510	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2964	151.6	1	SNP	p	D86N	0	.	.	256	258	GAC	571	573	GAC	178;178;177	G;A;C	165;160;163	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4510	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2964	151.6	1	SNP	p	S87R	0	.	.	259	261	AGT	574	576	AGT	178;176;176	A;G;T	165;162;159	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4510	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2964	151.6	1	SNP	p	S87W	0	.	.	259	261	AGT	574	576	AGT	178;176;176	A;G;T	165;162;159	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4510	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2964	151.6	1	SNP	p	S87I	0	.	.	259	261	AGT	574	576	AGT	178;176;176	A;G;T	165;162;159	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4510	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2964	151.6	1	SNP	p	S88P	0	.	.	262	264	TCC	577	579	TCC	179;178;177	T;C;C	162;163;164	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4016	parE	1986	1986	99.9	parE.l15.c17.ctg.1	2616	152.9	0	.	p	.	0	R427H	NONSYN	1279	1281	CGC	1564	1566	CAC	218;219;221	C;A;C,T	202;204;208,1	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4016	parE	1986	1986	99.9	parE.l15.c17.ctg.1	2616	152.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1513	1515	GGC	209;208;209	G;G;C	190;189;184	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.44.001	penA.44.001	1	1	539	3738	penA	1749	1749	99.94	penA.l6.c30.ctg.1	2260	164.0	0	.	p	.	0	L552P	NONSYN	1654	1656	CTG	1943	1945	CCG	153;154;151	C,T,G;C;G	123,1,1;124;121	.	.
penA.44.001	penA.44.001	1	1	539	3738	penA	1749	1749	99.94	penA.l6.c30.ctg.1	2260	164.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1220	1222	GCA	210;212;213	G;C;A	188;194;197	penA.44.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	539	3738	penA	1749	1749	99.94	penA.l6.c30.ctg.1	2260	164.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1223	1225	ATC	212;212;212	A;T;C,G	195;196;195,1	penA.44.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	539	3738	penA	1749	1749	99.94	penA.l6.c30.ctg.1	2260	164.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1235	1237	GTG	201;202;205	G;T;G	186;190;193	penA.44.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	539	3738	penA	1749	1749	99.94	penA.l6.c30.ctg.1	2260	164.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1235	1237	GTG	201;202;205	G;T;G	186;190;193	penA.44.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	539	3738	penA	1749	1749	99.94	penA.l6.c30.ctg.1	2260	164.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1739	1741	ACC	193;191;191	A;C;C	176;177;178	penA.44.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	539	3738	penA	1749	1749	99.94	penA.l6.c30.ctg.1	2260	164.0	1	SNP	p	T502P	0	.	.	1504	1506	ACG	1793	1795	ACG	198;197;200	A;C;G	154;157;155	penA.44.001:1:1:T502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	539	3738	penA	1749	1749	99.94	penA.l6.c30.ctg.1	2260	164.0	1	SNP	p	T502V	0	.	.	1504	1506	ACG	1793	1795	ACG	198;197;200	A;C;G	154;157;155	penA.44.001:1:1:T502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	539	3738	penA	1749	1749	99.94	penA.l6.c30.ctg.1	2260	164.0	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1916	1918	GGC	177;174;173	G;G;C	159;158;156	penA.44.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	539	3738	penA	1749	1749	99.94	penA.l6.c30.ctg.1	2260	164.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1925	1927	GGC	173;172;172	G;G;C	154;150;153	penA.44.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5260	ponA	2397	2397	100.0	ponA.l6.c30.ctg.1	3089	169.8	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1634	1636	CCG	172;172;173	C;C;G	151;159;149	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2064	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1680	121.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	525	525	C	120	C	106	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2666	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1455	181.9	0	.	p	.	0	T26A	NONSYN	76	78	ACC	340	342	GCC	252;252;255	G;C;C	233;231;237	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2666	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1455	181.9	0	.	p	.	0	N38E	NONSYN	112	114	AAT	376	378	GAA	256;258;254	G;A;A	237;238;232	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2666	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1455	181.9	0	.	p	.	0	N124S	NONSYN	370	372	AAT	634	636	AGT	181;180;180	A;G;T	168;168;166	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2666	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1455	181.9	0	.	p	.	0	N134D	NONSYN	400	402	AAT	664	666	GAT	164;162;164	G;A;T	156;153;152	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2666	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1455	181.9	0	.	p	.	0	P175S	NONSYN	523	525	CCA	787	789	TCA	226;226;226	T;C;A	214;213;216	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2666	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1455	181.9	0	.	p	.	0	A218V	NONSYN	652	654	GCC	916	918	GTC	219;220;218	G;T;C	203;202;203	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2666	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1455	181.9	0	.	p	.	0	F222S	NONSYN	664	666	TTT	928	930	TCT	215;216;215	T;C;T	200;203;202	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2666	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1455	181.9	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1246	1248	GCA	236;238;237	G;C;A	218;219;219	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2666	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1455	181.9	1	SNP	p	G120K	1	.	.	358	360	AAG	622	624	AAG	166;164;165	A;A;G	154;153;154	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2666	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1455	181.9	1	SNP	p	D121N	0	.	.	361	363	GAC	625	627	GAC	165;166;168	G;A;C	155;155;158	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2666	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1455	181.9	1	SNP	p	A121D	1	.	.	361	363	GAC	625	627	GAC	165;166;168	G;A;C	155;155;158	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	10200	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4973	204.7	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2085	2087	CAT	236;234;234	C;A,T;T	219;217,1;218	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1048	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	880	117.2	1	SNP	p	V57M	1	.	.	169	171	ATG	457	459	ATG	229;230;229	A,G;T;G	206,1;208;210	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
